J Cancer 2016; 7(14):1979-1983. doi:10.7150/jca.15966 This issue

Short Research Communication

Involvement of BAFF and APRIL in Resistance to Apoptosis of Acute Myeloid Leukemia

Lukasz Bolkun1✉, Kamil Grubczak2, Gabriela Schneider3, Paula Zembko2, Urszula Radzikowska2, Paulina Singh2, Janusz Kloczko1, Mariusz Z. Ratajczak3, Marcin Moniuszko2, Andrzej Eljaszewicz2 ✉

1. Department of Haematology, Medical University of Bialystok, Poland
2. Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Poland
3. Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, KY, USA

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Bolkun L, Grubczak K, Schneider G, Zembko P, Radzikowska U, Singh P, Kloczko J, Ratajczak MZ, Moniuszko M, Eljaszewicz A. Involvement of BAFF and APRIL in Resistance to Apoptosis of Acute Myeloid Leukemia. J Cancer 2016; 7(14):1979-1983. doi:10.7150/jca.15966. Available from https://www.jcancer.org/v07p1979.htm

File import instruction


B-cell activation factor of the TNF family (BAFF), and a proliferation-inducing ligand (APRIL), two members of the tumour necrosis factor (TNF) superfamily, beyond playing a significant role in normal B-cell development, promote survival and proliferation of malignant B cells. Both ligands interact with 3 receptors: BAFF-R, specific to BAFF, and TACI and BCMA which are shared by both BAFF and APRIL. Here we wished to investigate the potential role of these proteins in resistance of acute myeloid leukaemia (AML) blasts to apoptosis. We found that the levels of both mRNA and proteins of APRIL, BAFF and their receptors were expressed in leukaemic cells of 24 newly diagnosed, untreated AML patients. We also demonstrated that patients who did not further respond to induction therapy (NR) presented with significantly higher baseline APRIL and BAFF expression on AML blasts as compared to these subjects who, after induction, achieved complete remission (CR) following induction therapy. Moreover, we observed striking differences in baseline levels of BCMA between CR and NR patients as we did not find detectable expression of this receptor in the latter group of patients. Interestingly, we found that AML blasts collected at baseline from NR patients cultured in presence of exogenous BAFF and APRIL were significantly more resistant to spontaneous or drug-induced apoptosis as compared with cells derived from CR patients. Altogether, our data confirm that BAFF and APRIL signaling play important role in AML pathogenesis and susceptibility to cytotoxic therapy while measuring of BCMA expression on AML cells can become a novel prognostic factor for chemotherapy response.

Keywords: acute myeloid leukaemia, APRIL, BAFF, BCMA, treatment response